key: cord-0982183-k8r87cr3
authors: Jing, Wenyang; Procko, Erik
title: ACE2‐based decoy receptors for SARS coronavirus 2
date: 2021-05-18
journal: Proteins
DOI: 10.1002/prot.26140
sha: 27ba6747702f70540acf219f047f736a07a975ff
doc_id: 982183
cord_uid: k8r87cr3

SARS coronavirus 2 is neutralized by proteins that block receptor‐binding sites on spikes that project from the viral envelope. In particular, substantial research investment has advanced monoclonal antibody therapies to the clinic where they have shown partial efficacy in reducing viral burden and hospitalization. An alternative is to use the host entry receptor, angiotensin‐converting enzyme 2 (ACE2), as a soluble decoy that broadly blocks SARS‐associated coronaviruses with limited potential for viral escape. Here, we summarize efforts to engineer higher affinity variants of soluble ACE2 that rival the potency of affinity‐matured antibodies. Strategies have also been used to increase the valency of ACE2 decoys for avid spike interactions and to improve pharmacokinetics via IgG fusions. Finally, the intrinsic catalytic activity of ACE2 for the turnover of the vasoconstrictor angiotensin II may directly address COVID‐19 symptoms and protect against lung and cardiovascular injury, conferring dual mechanisms of action unachievable by monoclonal antibodies. Soluble ACE2 derivatives therefore have the potential to be next generation therapeutics for addressing the immediate needs of the current pandemic and possible future outbreaks.

Not long following its emergence in China in late 2019, SARS coronavirus 2 (SARS-CoV-2) became an unprecedented public health emergency for our generation. The absence of immunity, superspreader events 1 and presymptomatic 2 and asymptomatic 3, 4 transmission have all combined to favor this respiratory virus' global spread. The virus is devastating to the elderly and other vulnerable groups with certain predisposing conditions, and elicits surprisingly heterogenous disease symptoms collectively known as COVID-19, with the most common being fever, dry cough, hypoxemia and pneumonia, [5] [6] [7] [8] but also unusual neurological symptoms 9 and coagulopathy. 10 It remains unclear which aspects of disease are the result of disseminated virus infection of multiple tissues vs dysregulation of signaling pathways, including cytokine storms 11, 12 and aberrant angiotensin and kinin peptide processing. [13] [14] [15] Virus entry is mediated by interactions between the viral spike, a trimeric complex of protein S, and angiotensin-converting enzyme 2 (ACE2) on a host cell membrane. [16] [17] [18] [19] [20] [21] [22] [23] S is proteolytically processed as two subunits, S1 and S2, that remain noncovalently associated until ACE2 is bound by a receptor-binding domain (RBD) in the S1 subunit, triggering conformational changes that include S1 shedding, exposure of a fusion peptide in S2 and fusion of the viral envelope with the host membrane. 21, [24] [25] [26] [27] Antibodies targeting multiple epitopes on S, but especially the RBD, can block ACE2 engagement or prevent membrane fusion from occurring, and numerous monoclonal antibody therapies are now in preclinical and clinical development. [28] [29] [30] [31] [32] [33] However, coronaviruses have moderate to high-mutation rates 34, 35 and there is a perceived risk that drug resistant SARS-CoV-2 variants might begin circulating as antibody therapies are more widely used. New SARS-CoV-2 variants with increased transmissibility and partial immune escape have now emerged, [36] [37] [38] [39] and the virus will continue to mutate as it becomes endemic and population immunity builds. Indeed, Emergency Use Authorization from the U.S. Food and Drug Adnministration for anti-SARS-CoV-2 antibody bamlanivimab as a monotherapy has been withdrawn due to decreased efficacy against new virus variants (FDA revocation letter, April 16, 2021) . The risk of the virus acquiring resistance to monoclonal antibody therapies is mitigated by combining noncompeting antibodies in cocktails. 40 An alternative strategy is to use ACE2 itself as a soluble decoy receptor that competes for receptor-binding sites on S 22, [41] [42] [43] ( Figure 1 ). ACE2 is an 805 amino acid (a.a.) protein that comprises a protease domain (a.a. 19-615), a collectrin-like dimerization domain (a.a. 616-729), and a single-span transmembrane domain (a.a. 741-765). 16 It is widely expressed in vascular endothelium throughout the body and is notably found at high levels in the epithelia of the lung and gastrointestinal tract, 44 which are both important sites of infection and symptoms. 5, 6, 45 Neuropilins, transmembrane proteins with promiscuous interactions for growth factors and growth factor receptors, bind the C-terminus of the processed S1 subunit to further facilitate cell entry, and neuropilin expression likely influences SARS-CoV-2 tissue tropism. 46, 47 The major attraction of using an entry receptor like ACE2 as a soluble decoy is that, in principle, the virus has limited mutational mechanisms for escape without simultaneously losing affinity for the native, membrane anchored form. 48 Soluble decoy receptors are used clinically for a variety of indications, although none are yet approved drugs for viruses. 49 Wild type (WT), soluble ACE2 (sACE2) is an investigational drug for acute respiratory distress that has been rapidly repurposed as a SARS-CoV-2 antiviral 41 and was recently evaluated in a phase 2 COVID-19 clinical trial with promising results in severely ill patients (ClinicalTrials.gov Study NCT04335136; Apeiron Biologics media release 12 March 2021). This drug candidate has become the starting point for multiple engineering efforts to solve key issues surrounding pharmacokinetics, affinity, and avidity for the creation of next generation ACE2 derivatives with superior efficacy. These efforts are reviewed here.

Soluble decoy receptors should ideally bind the SARS-CoV-2 spike tighter than, and out-compete, the WT ACE2 receptor. Tight affinity is also necessary for effective virus neutralization at typical doses for biologic drugs. The importance of affinity is further emphasized when soluble decoys are considered against the therapeutic alternative of affinity-matured monoclonal antibodies, which bind S of SARS-CoV-2 with tight nanomolar to picomolar K d [28] [29] [30] 33 ; by comparison, WT sACE2 has only moderate affinity (K d ≈ 20 nM). 16, 50 To this end, mutagenic approaches, either targeted or through selection of diverse libraries of variants, provide a means for engineering decoy receptors with enhanced affinity.

In the first report 51 derivative with eight mutations (one predicted to decrease catalytic activity) that bound S of SARS-CoV-2 with over 100-fold tighter affinity. 58 Six of the mutations were among the most enriched in the deep mutational scan and it is worth noting that the works described in this review frequently converge on very similar mutations to a small number of sites ( Figure 2C ).

Romero investigated the influence on S protein binding of singlenucleotide variants (SNVs) in the ACE2 protease domain, evaluating nearly 4000 amino acid substitutions. 59 Mutations were made using error-prone PCR, a rapid and reliable way of generating library diversity but which fails to capture multiple nucleotide changes within a single codon, unless error rates are excessively high. The library of the ACE2 protease domain was screened by yeast surface display ( Figure 2B ) and while most mutations decreased binding (it is, after all, easy to "break" a protein through random mutagenesis), approximately 4% of mutations were found to increase RBD binding. While mutations in the active site tended to have little effect (with the caveat that the background ACE2 sequence used for library generation already had catalytic activity knocked out), the authors found that residues in the chloride-binding site of ACE2, which regulates its peptidase activity 60 57 Binding was assayed using the method previously developed for deep mutagenesis, 50 with human cells expressing the ACE2 library incubated with RBD-sfGFP and sorted by FACS.

Mutations within the "PD1" region were selected first, followed by mutagenesis within the "PD2" region and additional rounds of selection, although additional mutations within the PD2 region did not substantially improve affinity. Molecular interactions with the RBD are mostly localized to the ACE2 N-terminus 16 encompassed in their PD1

library. The ACE2 variant identified with highest affinity, termed 3N39 with seven substitutions ( Figure 2C ), bound RBD with pic-

There is a risk during in vitro affinity maturation that a decoy receptor will be "over-engineered" or "over-fitted" for its tar- The Kortemme, Hobman, and Wells groups went even further in using multiple rounds of engineering, diversification, and selection to drive down the dissociation constant to the picomolar range. 54 Figure 2C ). It was also independently confirmed that additional increases in apparent affinity can be achieved through inclusion of the ACE2 collectrinlike dimerization domain for avid binding and protein stabilization. 50, 54, 55 In this study, deliberate action was taken to inactivate ACE2 enzymatic activity. This has historically been done by mutating two critical Zn 2+ -coordinating residues (H374N and H378N) , 61 but because these substitutions resulted in undesirable destabilization in the variant background, an alternative mutation was adopted: H345L

within the substrate-binding cavity. It has since been noted that a common assay for measuring ACE2 catalytic activity with a fluorogenic substrate mimic does not necessarily reflect proteolysis of the relevant in vivo substrate (angiotensin II) and therefore some caution must be used in interpreting measurements of catalysis reported by different groups. 62 ACE2 mutants of residue H345 in particular may retain proteolytic activity toward angiotensin II. While the rationale for this mutation is the elimination of vasodilatory effects due to excess ACE2 peptidase activity that may cause hypotension, it is worth considering the potential benefits of keeping enzymatic activity (discussed below).

Pangolin (Pangolin-CoV-2020) and bat (isolate RaTG13) coronaviruses, in addition to human SARS-CoV-1 and -2, can initiate membrane fusion using not only human ACE2 but many other animal orthologs. 55 This informed the substitution of human ACE2-D30 for glutamate, 55 which is found in ACE2 of other species and is able to better reach K417 of the RBD for salt bridge formation. 16, 17 In addition, inclusion of the dimerization domain together with the protease domain further facilitated the engineering of a sACE2-Ig fusion protein effective against multiple betacoronavirus strains. The discovery of the affinity-enhancing D30E mutation and benefits of including the dimerization domain overlap with independent work by others. 50, 54 Another contributing factor was increased avidity (to be discussed further below) due to design of a tetrameric sACE2-Ig configuration. 55 The concept of borrowing residues from the ACE2 proteins of other species that bind zoonotic coronaviruses with naturally higher affinity than the human ortholog has been taken even further. 63 Residues in human ACE2 were systematically substituted with their counterparts in high-affinity bat ACE2 orthologs, providing a set of five mutations that could be combined to yield an sACE2 2 -Fc derivative with increased efficacy for pseudovirus neutralization. Overall, it is apparent from all these studies that a truly effective therapeutic approach utilizing decoy ACE2 receptors will likely incorporate a multifaceted strategy of affinity enrichment, avidity, and Fc fusions.

One final aspect to touch upon regarding affinity enhancement through mutagenesis is the connection between binding affinity and ACE2 enzymatic activity. For example, the sACE2 2 .v2.4 variant has reduced catalytic activity even though its three amino acid substitutions are not within the active site, 50 thus demonstrating potentially unappreciated coupling between S affinity and ACE2 catalysis. Others have observed that some mutations that knock out ACE2 activity can increase S binding, 64 although many mutations in the active site have no effect on S affinity. 50, 59 Bioinformatics and mutagenesis based on comparisons of ACE2 between species reveals epistatic relationships between residues at the virus binding surface and the active site. 65 Furthermore, we again highlight the key finding by Heinzelman and

Romero that mutations to a chloride-binding motif of ACE2, which is 40 Å from the RBD interface and is directly involved in regulating peptidase activity, can affect spike affinity, possibly due to conformational effects. 59 The binding of trimeric SARS-CoV-2 spike protein to WT ACE2 also increases its peptidase activity 3-to 10-fold, with the SARS-CoV-2 RBD inducing bending of the N-terminal protease subdomain toward the C-terminal protease subdomain "…reminiscent of a closing dam." 66 Although the precise mechanisms remain unclear, there are nonetheless multiple clues incriminating ACE2 conformation and dynamics on both catalytic activity and S affinity. We believe from a therapeutic perspective (to be discussed further below), maintaining catalytic activity is preferable due to the protective effects of ACE2 products on the pulmonary and cardiovascular systems.

Despite a recent clinical trial of WT sACE2 2 in Europe 67 and the studies reviewed above demonstrating the realization of picomolar affinity decoy receptors, it is likely that low sACE2 serum stability will limit its successful application as a therapeutic. The serum half-life of dimeric More recently with the emergence of SARS-CoV-2, multiple groups have explored IgG1-Fc fusions of sACE2 or sACE2 2 , consistently finding no adverse toxicity in small animals. 42 Only a single study shows long serum half-life of both moieties by use of a sandwich ELISA with an anti-ACE2 capture antibody and anti-IgG1 detection antibody. 62 We believe these discrepancies point 

Most reports describing the engineering of sACE2 to enhance its affinity through targeted substitutions, or to improve pharmacokinetics through Fc fusions, have deliberately eliminated ACE2 catalytic activity. 42, 54, 58, 64, 85 The assumption is that administration of a catalytically active decoy receptor will adversely interact with physiology to have unacceptable toxicity. Soluble decoy receptors for other viruses have also been engineered to eliminate the normal biological activity for safety and efficacy reasons. 101 However, there are strong arguments that ACE2 catalytic activity might be beneficial for treating COVID-19 symptoms.

In the renin-angiotensin system (RAS), a set of proteases regulates the production of angiotensin peptide hormones 102, 103 ( Figure 3B ). Renin is released by the kidneys when renal blood flow is low and it catalyzes the conversion of angiotensinogen in the blood to angiotensin I (Ang-I). Ang-I is in turn a substrate for angiotensinconverting enzyme (ACE or ACE1), which cleaves the peptide to produce the vasoconstrictor Ang-II that has a wide range of effects through the angiotensin II type 1 receptor (AT 1 R). Ang-II promotes vasoconstriction and elevated blood pressure and volume, and under conditions where Ang-II is high there can be increased inflammation, myocardial fibrosis, and thrombosis. Ang-II is proteolyzed by ACE2 to produce Ang-1-7, 104-107 which has vasodilatory properties and is cardioprotective. 108 Different mutations have been introduced into sACE2 to eliminate catalytic activity, the most common being H374N and H378N to prevent coordination of an essential Zn 2+ ion. 61 Others have used alternative mutations within the ACE2 active site, 54,64 although it has recently been shown that a common fluorescence assay to assess ACE2 enzymatic activity does not accurately represent proteolysis of Ang-II, suggesting caution when considering claims surrounding mutational effects on catalysis. 62 A number of ACE2 variants with reduced catalytic activity bind slightly tighter to SARS-CoV-2 S, suggesting possible conformational coupling between the catalytic and S binding sites.

The apparent affinity of ACE2 for S incorporates both affinity (site specific binding strength) and avidity (the total sum of all binding interactions). ACE2 is a natural dimer and dimeric sACE2 2 is orders of magnitude more effective at neutralizing authentic virus than the monomeric sACE2 protease domain. 50 The three subunits in a trimeric S spike are conformationally heterogenous, and the RBDs may be exposed for ACE2 interactions in an "up"/"open" conformation or hidden in a "down"/"closed" conformation. 18 RBDs up and accessible for ACE2 interactions. [118] [119] [120] There is limited evidence that dimeric ACE2 2 can bridge two S subunits in a single trimeric spike (ie, intra-spike avidity) 121 and atomic structures suggest the spatial orientation of natural dimeric ACE2 2 is incompatible with binding two RBDs in a single S trimer 16, 122 (Figure 4 ). This is not to say that more than one ACE2 2 dimer cannot bind a trimeric spike, and indeed structures have been determined with all three RBDs of trimeric S in the up state and bound to three ACE2 protease domains. 122 Rather, a single ACE2 2 dimer in which the orientations of the protease domains are governed by the collectrin-like dimerization domains cannot simultaneously engage two subunits in a single S trimer, unless spike flexibility is greater than is captured in current high-resolution structures. Avidity effects are therefore most likely due to dimeric ACE2 2 cross-linking two separate viral spikes, which is supported by cryo-electron tomography showing moderate spike density on the viral envelope suitable for bridging interactions. [118] [119] [120] We speculate that clustering of dimeric ACE2 2 via bridging interactions with S trimers at the virus-cell membrane synapse might even aid endocytosis and infection. However, protein engineers are not limited to the geometric architecture of natural ACE2 2 dimers and have at their disposal tools for creating higher multimeric forms that may sterically complement exposed RBDs on native S trimers ( Figure 5 ). Lastly, avidity has been increased by fusing an anti-S antibody to sACE2 to create a hybrid, biparatopic ACE2-IgG fusion. 125 forms. There is also precedence for hyperstable miniproteins being non-immunogenic. 131 However, small proteins tend to have short serum half-lives and while this can be remedied by fusion to IgG1-Fc, this negates their primary advantage of bacterial expression. Most likely, miniproteins will need to be administered directly to the nasal passages or lungs to compensate for poor serum stability, as was done in animal experiments. 130 This is not necessarily a disadvantage and may contrast favorably in clinical practice with convalescent plasma and monoclonal antibodies that are infused intravenously. The major disadvantage of these miniproteins is that, while they might mimic some aspects of ACE2 binding in the sense that they use helical segments at the interface, they are not true receptors and lack the breadth of ACE2 derivatives. To begin with, the designed miniproteins poorly bind S of SARS-CoV-1 and are not pan-specific inhibitors. A deep mutational scan of the SARS-CoV-2 RBD also provided hints of possible escape mutations, even if not common, 130 and at least one of the designed miniproteins with exceptionally tight affinity to S from the original Wuhan SARS-CoV-2 isolate has a near total loss of affinity to newer virus variants in circulation. 132 Computational calculations predict that the miniproteins in general will have reduced affinity to highly transmissible SARS-CoV-2 variants carrying a N501Y mutation in S; 133 this mutation markedly increases affinity between ACE2 and the RBD. 48 We propose that at least some miniproteins are "overfitted" for the receptor-binding surface of a single S sequence, such that they are at risk of reduced potency as S mutates. There may be important lessons here for the engineering of ACE2 mutants and it is likely there is a balance between achieving ever higher affinity at the expense of breadth as ACE2 derivatives increasingly look different from WT receptors. is no reason to expect soluble ACE2 decoys cannot be as effective as monoclonals in reducing viral load in patients. Anti-SARS-CoV-2 monoclonals have received a preferential regulatory environment for clinical advancement due to an in-depth understanding of antibody biochemistry, pharmacokinetics, and general toxicology. Decoy receptors will always come with additional risks related to immunogenicity and safety, and the outstanding question for the community is whether they provide truly unique benefits that outweigh those risks.

The advantages of soluble ACE2 are its breadth against SARSassociated coronaviruses and its potential for alleviating COVID-19 symptoms through intrinsic enzymatic activity. We believe these advantages justify continued efforts toward advancing these proteins to the clinic.

Erik Procko was supported by NIH award R01AI129719.

The University of Illinois has filed a provisional patent for engineered decoy receptors with Erik Procko as an inventor. Erik Procko is a cofounder of Orthogonal Biologics, Inc.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Wenyang Jing https://orcid.org/0000-0002-8163-3998

Erik Procko https://orcid.org/0000-0002-0028-490X

Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong

Temporal dynamics in viral shedding and transmissibility of COVID-19

Presumed asymptomatic carrier transmission of COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

A novel coronavirus from patients with pneumonia in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

Neurological associations of COVID-19

COVID-19 update: Covid-19-associated coagulopathy

Cytokine storm in COVID-19: pathogenesis and overview of antiinflammatory agents used in treatment

Cytokine storm induced by SARS-CoV-2

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 Infec

A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-Long structural studies of SARS coronavirus

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Chapter four -structural insights into coronavirus entry

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Broad neutralization of SARSrelated viruses by human monoclonal antibodies

A human monoclonal antibody blocking SARS-CoV-2 infection

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Mosaic structure of human coronavirus NL63, one thousand years of evolution

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data

Virological. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

SARS-CoV-2 501Y.V2 escapes neutralization by south African COVID-19 donor plasma

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Neuropilin-1 is a host factor for SARS-CoV-2 infection

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

THPdb: database of FDAapproved peptide and protein therapeutics

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2

Deep mutagenesis in the study of COVID-19: a technical overview for the proteomics community

Engineering and characterization of a superfolder green fluorescent protein

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

SARS-CoV-2 and three related coronaviruses utilize multiple ACE2 Orthologs and are potently blocked by an improved ACE2-Ig

Coronavirus biology and replication: implications for SARS-CoV-2

High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamsters

Coronacept -a potent immunoadhesin against SARS-CoV-2

Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein

Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis

Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2

Designed variants of ACE2-fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects

Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-fc neutralization of SARS-CoV-2

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

The ancient cardioprotective mechanisms of ACE2 bestow SARS-CoV-2 with a wide host range

High affinity binding of SARS-cov-2 spike protein enhances ACE2 carboxypeptidase activity

Human recombinant soluble ACE2 in severe COVID-19

Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

Fusion proteins for half-life extension of biologics as a strategy to make biobetters

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Angiotensin-converting enzyme 2 protects from lethal avian influenza a H5N1 infections

Recombinant angiotensinconverting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets

ACE2 improves right ventricular function in a pressure overload model

Novel ACE2-fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2. Hypertension

Intraperitoneal route of drug administration: should it be used in experimental animal studies?

Absorption of plasma proteins from peritoneal cavity of normal rats

An ACE2 microbody containing a single immunoglobulin fc domain is a potent inhibitor of SARS-CoV-2

A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection

Intranasal gene therapy to prevent infection by SARS-CoV-2 variants

Conceptual approaches to modulating antibody effector functions and circulation half-life

Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-fc fusion protein with a stabilized hinge region

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Antibody-dependent enhancement of severe dengue disease in humans

Antibody-dependent enhancement of virus infection and disease

Learning from the past: development of safe and effective COVID-19 vaccines

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Molecular mechanism for antibodydependent enhancement of coronavirus entry

Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis

No evidence for human monocyte-derived macrophage infection and antibody-mediated enhancement of SARS-CoV-2 infection

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the reninangiotensin system

Engineered receptors for human cytomegalovirus that are orthogonal to normal human biology

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th anniversary of the discovery of ACE2

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Angiotensin II receptors and drug discovery in cardiovascular disease

A mechanistic model and therapeutic interventions for covid-19 involving a ras-mediated bradykinin storm

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

Modulation of TNFα-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation

Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients

Serum ACE-2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges

Molecular architecture of the SARS-CoV-2 virus

Trimeric SARS-CoV-2 spike interacts with dimeric ACE2 with limited intra-spike avidity

Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains

Engineered trimeric ACE2 binds viral spike protein and locks it in "three-up" conformation to potently inhibit SARS-CoV-2 infection

A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

Membrane nanoparticles Derived from ACE2-rich cells block SARS-CoV-2 infection

Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 spike protein-containing virus

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

Massively parallel de novo protein design for targeted therapeutics

Rapid characterization of spike variants via mammalian cell surface display

Fast prediction of binding affinities of the SARS-CoV-2 spike protein mutant N501Y (UKvariant) with ACE2 and miniprotein drug candidates

How to cite this article: Jing W, Procko E. ACE2-based decoy receptors for SARS coronavirus 2